Company profile: California Stem Cell
1.1 - Company Overview
Company description
- Provider of high-purity human cells for therapeutic development and clinical applications, leveraging proprietary methods for scalable production of human motor neurons, neuronal progenitors, cardiac muscle, and sino-atrial node cells. Privately held; founded in 2005.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to California Stem Cell
Acousia Therapeutics
HQ: Germany
Website
- Description: Provider of small-molecule therapeutics for sensorineural hearing loss, with expertise in identifying and developing drug candidates to enhance and preserve natural hearing. Products include ACOU085, an etiology-agnostic otoprotective candidate preventing chemotherapy-induced hearing loss and sensory hair cell death, and ACOU082, an oral Kv7.4 activator to enhance natural hearing and protect against age-related loss.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acousia Therapeutics company profile →
PeproMene Bio
HQ: United States
Website
- Description: Provider of BAFFR-targeted immunotherapies: BAFFR CAR-T cells for B cell malignancies and autoimmune diseases; BAFFR BiTE T cell engagers targeting CD3 and BAFF-R, showing in vitro and in vivo tumor efficacy; and allogeneic BAFFR CAR NK cells offering a potential off-the-shelf treatment option. A virtual, privately funded biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PeproMene Bio company profile →
Angioblast
HQ: United States
Website
- Description: Provider of biotechnology therapeutic products targeting cardiovascular diseases, developing and commercializing adult stem cell therapies, protein therapeutics, gene silencing solutions, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, DNAzymes, and MPC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angioblast company profile →
Stemedica
HQ: United States
Website
- Description: Provider of allogeneic, ischemia-tolerant progenitor cell therapies in clinical development, including itMSCs for ischemic stroke and Alzheimer’s, itNSCs for spinal cord injury, Progenitor Multi-Cell Therapy for stroke, and Progenitor Cell and Protein Combination Therapy for Alzheimer’s; plus BioSmart Technology for manufacturing non-embryonic progenitor cells and StemPro Neural Stem Cells (marketed by ThermoFisher) for research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stemedica company profile →
Trail Bio
HQ: United States
Website
- Description: Provider of human iPSC-derived cells and optimization technologies for drug discovery and cell therapies. Offers the HD-DoE Technology Platform, applying high-dimensional design-of-experiments to optimize cell growth and differentiation, and TrailBio Cells. Portfolio includes TrailBio Pre-Myelinating Oligodendrocytes Kit, Vascular Leptomeningeal Cells, and Insulin-Producing Islet-Like Clusters for screening and disease modeling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trail Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for California Stem Cell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to California Stem Cell
2.2 - Growth funds investing in similar companies to California Stem Cell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for California Stem Cell
4.2 - Public trading comparable groups for California Stem Cell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →